IPO Timeline Raw facts
Company Overview
| Stock Name | Vigonvita-B |
|---|---|
| Stock Code | 02630 |
| Company Full Name | Vigonvita Life Sciences Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | introduction of our Core Products and VV116: (cid:129) LV232 |
| Listing Date | 2025-11-06 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | No. 108, Yuxin Road Suzhou Industrial Park District Suzhou, PRC |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場2座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.vigonvita.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | Computershare Hong Kong Investor |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 33.37 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 6,673 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2025-10-28 to 2025-11-03 |
| Global Offering Shares | 17,597,800 shares |
| HK Public Offer Shares (Initial) | 1,759,800 shares (10.0%) |
| Public Offer Lots (Initial) | 8,799lots (Pool A4,399lots,Pool B4,400lots) |
| International Placing Shares (Initial) | 15,838,000 shares (90.0%) |
| Offer Ratio | ~10.5% |
| Total Shares Post-IPO | 167,597,800 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | 中信证券(香港)有限公司 CE AAK249 |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 587,238,586 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 6,674 |
| 2 lots | 400 | HK$ 13,348 |
| 3 lots | 600 | HK$ 20,022 |
| 4 lots | 800 | HK$ 26,696 |
| 5 lots | 1,000 | HK$ 33,370 |
| 6 lots | 1,200 | HK$ 40,044 |
| 7 lots | 1,400 | HK$ 46,718 |
| 8 lots | 1,600 | HK$ 53,392 |
| 9 lots | 1,800 | HK$ 60,066 |
| 10 lots | 2,000 | HK$ 66,740 |
| 15 lots | 3,000 | HK$ 100,110 |
| 20 lots | 4,000 | HK$ 133,480 |
| 25 lots | 5,000 | HK$ 166,850 |
| 30 lots | 6,000 | HK$ 200,220 |
| 35 lots | 7,000 | HK$ 233,590 |
| 40 lots | 8,000 | HK$ 266,960 |
| 45 lots | 9,000 | HK$ 300,330 |
| 50 lots | 10,000 | HK$ 333,700 |
| 75 lots | 15,000 | HK$ 500,550 |
| 100 lots | 20,000 | HK$ 667,400 |
| 125 lots | 25,000 | HK$ 834,250 |
| 150 lots | 30,000 | HK$ 1,001,100 |
| 175 lots | 35,000 | HK$ 1,167,950 |
| 200 lots | 40,000 | HK$ 1,334,800 |
| 225 lots | 45,000 | HK$ 1,501,650 |
| 250 lots | 50,000 | HK$ 1,668,500 |
| 300 lots | 60,000 | HK$ 2,002,200 |
| 350 lots | 70,000 | HK$ 2,335,900 |
| 400 lots | 80,000 | HK$ 2,669,600 |
| 450 lots | 90,000 | HK$ 3,003,300 |
| 500 lots | 100,000 | HK$ 3,337,000 |
| 600 lots | 120,000 | HK$ 4,004,400 |
| 700 lots | 140,000 | HK$ 4,671,800 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 800 lots | 160,000 | HK$ 5,339,200 |
| 900 lots | 180,000 | HK$ 6,006,600 |
| 1,000 lots | 200,000 | HK$ 6,674,000 |
| 1,250 lots | 250,000 | HK$ 8,342,500 |
| 1,500 lots | 300,000 | HK$ 10,011,000 |
| 1,750 lots | 350,000 | HK$ 11,679,500 |
| 2,000 lots | 400,000 | HK$ 13,348,000 |
| 2,250 lots | 450,000 | HK$ 15,016,500 |
| 2,500 lots | 500,000 | HK$ 16,685,000 |
| 3,000 lots | 600,000 | HK$ 20,022,000 |
| 3,500 lots | 700,000 | HK$ 23,359,000 |
| 4,000 lots | 800,000 | HK$ 26,696,000 |
| 4,399 lots | 879,800 | HK$ 29,358,926 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 13.86B |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap met, expected inclusion ~2027-03-08 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,592,738,586 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 2,225,015,928 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB217.6 million |
| Period-End Cash Balance | RMB 121.14 million |
| Listing Expenses | ~HK$ 59,600,000 |
| Listing Expenses / Funds Raised | ~10.3% |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 82.0 |
|---|---|
| First Day Open | HK$ 95.0 |
| First Day Change | 145.73% |
| First Day Volume | 5534410.0 |
| First Day Turnover | 486174000.0 |
| Use of Proceeds | 1、38.0%(或約198.0百萬港元)將用于我們核心產品的研發;
2、27.0%(或約140.7百萬港元)將用于我們其他候選產品的研發;
3、10.0%(或約52.1百萬港元)將用于建設我們的青島工廠;
4、15.0%(或約78.2百萬港元)將用于強化我們的銷售及營銷能力;
5、10.0%(或約52.1百萬港元),將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
美迈斯律师事务所 君合律师事务所 竞天公诚律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
苏利文•克伦威尔律师事务所(香港)有限法律责任合伙 金杜律师事务所 |
| Auditor and Reporting Accountant | 德勤•关黄陈方会计师行 |
| Industry Advisor | 灼识行业咨询有限公司 |
| Compliance Advisor | Somerley Capital Limited CE BAU754 |
| Receiving Banks |
中国银行(香港)有限公司 中信银行(国际)有限公司 |
Cornerstone Investors
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Dr. Tian Guanghui | Dr. Tian Guanghui |
| Company Secretary | Ms. Guo Ting | Ms. Guo Ting |
| Executive Director | 田广辉 | Tian Guanghui |
| Non-Executive Director | 刘浩轩 | Liu Haoxuan |
| Independent Non-Executive Director | 鞠佃文 | Ju Dianwen |
| Executive Director | 胡天文 | Hu Tianwen |
| Independent Non-Executive Director | 曹新文 | Cao Xinwen |
| Independent Non-Executive Director | 徐宏喜 | Xu Hongxi |
| Independent Non-Executive Director | 杨汝磊 | Yang Rulei |
| Independent Non-Executive Director | 周洪举 | Zhou Hongju |
| Independent Non-Executive Director | 李建 | Li Jian |
Major Shareholders
| Major Shareholders & Holdings | Dr. Shen holds 82,461,110 unlisted shares (representing 49.20%), Ms. Jin Jie holds 2,272,478 unlisted shares (representing 1.36%), Dr. Tian holds 5,726,644 unlisted shares and 8,589,967 H shares (in total representing 8.54%), Suzhou Hesheng holds 6,783,348 H shares (representing 4.05%), Ms. Jin Qing holds 5,517,145 H shares (representing 3.29%), Xieyao Kexin holds 4,370,157 H shares (representing 2.61%), Xieyao Kesheng holds 1,032,546 H shares (representing 0.62%), Suzhou Meilingge holds 1,092,539 H shares (representing 0.65%), other pre-IPO investors in total hold 13.34%, and public shareholders hold 10.50%. |
|---|
Market Sentiment
The IPO saw extraordinary market enthusiasm with an oversubscription ratio of 6238.42x, indicating intense demand for the shares. The overall hit rate of just 3.32% reflects a very low allocation probability for retail investors, typical of highly sought-after biotech listings under Chapter 18A. Final pricing at HK$33.37 likely captured strong institutional interest, though the absence of an indicative range limits pricing insight. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
Tier-specific allocation data is not provided, preventing any analysis of distribution patterns or potential anomalies such as 甲尾-乙头 inefficiencies. Without detailed breakdowns of lots applied and allocated per tier, it is impossible to assess broker fee efficiency or unusual winner ratios at key thresholds. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
The demographic data for this IPO is not available; all recorded percentages for mainland and Hong Kong participation show zero, likely indicating missing or unreported figures. Consequently, no conclusions can be drawn about regional concentration, gender distribution, or Mainland China participation rates. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




